Bayerische Motoren Werke ADR (BMWYY)

Limo SF VIP (888-888-0195) announces an expanded VIP transportation service available in the San Francisco Bay Area, offering exclusive experiences suited to high-end weddings, special events, luxury city tours, wine tours, and airport transfers.

UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast for 2025 after its customers on Medicare Advantage made use of their policies a lot more than the company had anticipated. The first quarter of the year registered a lower financial performance than the company had expected.

Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number of countries granting protection to 46.

Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases were reported globally, representing a 16% decrease compared to the previous period ( https://ibn.fm/viChU ). However, during the same timeframe, approximately 4,500 new deaths were reported, marking a 28% increase. This underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.

A new study whose findings appeared in the journal Heliyon has found that individuals that suffered neglect, abuse and other forms of maltreatment during their childhood had a notably elevated risk of being diagnosed with chronic immune-related disorders later on in their lives. Psoriasis and rheumatoid arthritis were particularly noted in the study subjects and women exhibited a higher likelihood of developing these immune disorders.

Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. Sheridan is one of 27 Irish entrepreneurs recognized for their leadership and impact, with finalists selected from across 24 companies generating more than €1 billion in annual revenue.

Kairos Pharma (NYSE American: KAPA) announced that the U.S. Department of Defense has awarded $876,000 to Cedars-Sinai Medical Center to support biomarker research for Kairos’ Phase 1 trial of ENV105 in EGFR-driven non-small cell lung cancer. The study focuses on patients developing resistance to osimertinib, aiming to identify those who may benefit from early intervention with ENV105. The funding will support research in Dr. Neil Bhowmick’s lab and aligns with Kairos’ strategy to improve long-term outcomes through targeted therapy and precision monitoring.

The global market for brain tumor treatments is experiencing significant transformation powered by advances in immunotherapy, personalized medicine and targeted therapy. The market is projected to grow at a 7.2% CAGR to reach $7.15 billion by 2035, according to a report published by Future Market Insights.

April 17, 2025 -- Precision Meets Passion: The Foreign Affairs Auto Difference

April 17, 2025 -- The Importance of Specialized Care for European Vehicles

April 17, 2025 -- Why BMW Owners Choose Foreign Affairs Auto

"Not Your Basic Locksmith" (682-344-1957) has expanded its professional car locksmith services in Arlington, TX, offering fast, affordable, and efficient solutions for automotive lockouts, key programming, and ignition repair.

April 12, 2025 -- Certified Excellence for European Engineering

April 11, 2025 -- A Legacy Built on European Engineering Expertise

Milwaukee, WI () April 10, 2025 -- Milwaukee's trusted auto service provider enhances customer experience with a new digital platform for seamless vehicle repairs and maintenance.

Many patients who have had a stroke often suffer secondary brain damage as a result of the inflammation that is triggered during the stroke. Scientists have been working to find ways to forestall this secondary brain damage and a recent preclinical study conducted by a team at UTHealth Houston could provide a viable way to address neuroinflammation after stroke episodes.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research ( https://ibn.fm/OpnDo ). The report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix’s diverse product pipeline, financial health and strategic positioning within the biopharmaceutical industry.

NEW YORK - April 9, 2025 - PRLog -- WongDoody, a global creative technology agency and an Infosys company, today announces the hiring of Falk Eumann as Executive Creative Director, North America. This strategic hire further reinforces the agency's commitment to delivering intelligent marketing and experiences powered by creativity, technology, and AI.With more than two decades of creative leadership experience, Falk brings to WongDoody an entrepreneurial mindset and a bold, global perspective. Based in New York, he will help lead the creative vision for the agency's North America operations, working closely with teams across the U.S. to craft experiences that are not only compelling but technologically advanced. With more than 15 years of focus in the digital space, his approach blends technology, design, and storytelling to build purpose-driven and business-relevant experiences."Falk's ability to lead high-performing creative teams and deliver AI and tech-centric customer solutions that help businesses evolve is exactly the kind of leadership we're building for the future," said Laura Davis, Managing Director, U.S., WongDoody.Prior to joining WongDoody, Falk led world-class creative organizations and contributed to campaigns for some of the world's most recognized brands, including T-Mobile, Lufthansa, BMW, Mercedes-Benz, and many more. His work has been honored by the Emmys, Clios, Cannes Lions, and The One Show, among others."This is a tremendously exciting time to join WongDoody," said Falk Eumann. "The opportunity to merge human-centered storytelling with next-gen technology is more relevant than ever—and I look forward to pushing the boundaries of what's possible alongside this incredibly talented team."This appointment comes as WongDoody continues to expand its U.S. footprint and build on its expertise in experience design, digital marketing, and AI-powered innovation.About WongDoody: WongDoody is the creative technology agency from Infosys that creates intelligent marketing and experiences helping unlock what's next for people and brands. With 22 studios and 2000+ employees around the globe, we serve clients in more than 55 countries with intelligent, human-centered creativity that solves business problems. We unlock future potential with AI-driven marketing, data-backed strategies, intelligent products, services and platforms, virtual and augmented reality, digital twins, and next-gen AI content that people love. For more information visit https://www.wongdoody.com.

A new study has uncovered key drivers of brain cancer growth that could make it possible to predict or even slow down the rate at which these tumors regrow. This could open a new chapter in personalized cancer treatment.

In the fast-paced world of automotive customization, TMM Racing is redefining innovation with its cutting-edge LCD license plate covers. Founded by Prabhat Nallamilli, Rishith Mishra, and Subhash Nallamilli, the company is transforming the automotive accessories market by integrating advanced LCD technology that allows license plates to switch between clear and blacked-out states in milliseconds—all at the push of a button.

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has entered into an Associate Partnership agreement with Charlotte FC to raise awareness of its flagship brands, including AI Tape and AVERSA. The company plans to leverage the partnership to enhance exposure for AI Tape, which is manufactured in the Charlotte region through its Pocono Pharmaceutical subsidiary. Nutriband also aims to spotlight its AVERSA platform, touted as a potential first-in-class abuse-deterrent patch for chronic pain management.

Sunshine Biopharma (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, has closed its previously announced registered direct offering with institutional investors of approximately $2.46 million shares of common stock and pre-funded warrants at a price of $2.07 per share of common stock. The company received aggregate gross proceeds of approximately $2.46 million from the offering, of which it intends to use the net for general corporate purposes and working capital. Aegis Capital Corp. acted as exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the company, and Kaufman & Canoles, P.C. acted as counsel to Aegis.

ADHD, or attention deficit hyperactivity disorder, is usually diagnosed during one’s childhood, but more adults are being diagnosed with this condition. Experts have observed that among adults diagnosed with ADHD, the likelihood of developing dementia is heightened, but it hasn’t been clear why this is the case. Now a new study suggests a possible explanation for the increased possibility of dementia development among adult ADHD sufferers.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate, HyBryte(TM) (“SGX301”), has already demonstrated positive results in a prior phase 3 trial, and Soligenix is now conducting a phase 3 replication study to further validate its efficacy and safety ( https://ibn.fm/zdRnQ ). This development marks an important milestone in the company’s mission to address an urgent medical need in a condition with limited treatment options.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will participate in the upcoming Jones Las Vegas Technology and Innovation Conference at The Venetian Resort. The April 8-9 event, organized by JonesTrading and supported by B2i Digital, provides a platform for direct engagement between innovative companies and institutional investors ( https://ibn.fm/fIKDc ).